| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2021 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CONSTELLATION PHARMCETICLS I | 8 | Q3 2020 | 33.8% |
| GRITSTONE ONCOLOGY INC | 8 | Q3 2020 | 42.2% |
| ARCUS BIOSCIENCES INC | 7 | Q2 2020 | 33.6% |
| NGM BIOPHARMACEUTICALS INC | 6 | Q3 2020 | 69.6% |
| RAPT Therapeutics Inc | 4 | Q3 2020 | 22.3% |
| Revolution Medicines Inc | 3 | Q3 2020 | 22.7% |
| Immune Design Corp. | 2 | Q1 2019 | 20.7% |
| ORIC Pharmaceuticals Inc. | 2 | Q3 2020 | 13.4% |
| Nurix Therapeutics Inc | 1 | Q3 2020 | 19.2% |
View Svennilson Peter's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-08 |
| 4 | 2023-11-17 |
| 4 | 2023-02-01 |
| 4 | 2023-01-25 |
| 4 | 2023-01-23 |
| 4 | 2023-01-17 |
| 4 | 2023-01-12 |
| 4 | 2022-12-14 |
| 4 | 2022-11-23 |
| 4 | 2022-11-07 |
View Svennilson Peter's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.